Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVA · IEX Real-Time Price · USD
14.11
-0.32 (-2.22%)
At close: Mar 28, 2024, 4:00 PM
14.00
-0.11 (-0.78%)
After-hours: Mar 28, 2024, 7:34 PM EDT

Company Description

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.

The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM.

In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.

The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.

It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH.

The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries logo
Country Israel
Founded 1901
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 37,851
CEO Richard D. Francis

Contact Details

Address:
Teva Pharmaceutical Industries Limited, 124 Dvora Hanevi'a St.
Tel Aviv, L3 6944020
Israel
Phone 972 (3) 914-8213
Website tevapharm.com

Stock Details

Ticker Symbol TEVA
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000818686
CUSIP Number 881624209
ISIN Number US8816242098
SIC Code 2834

Key Executives

Name Position
Eliyahu Sharon Kalif Executive Vice President and Chief Financial Officer
Eric Drape Executive Vice President of Global Operations
Mark Sabag Executive Vice President of International Markets Commercial
Richard D. Francis President, Chief Executive Officer and Director
Amir Weiss Senior Vice President and Chief Accounting Officer
Ran Meir Head of Investor Relations
Dov Bergwerk Acting Chief Legal Officer and Corporate Secretary
Kathleen Veit Senior Vice President, Global Compliance and Ethics Officer
Vikki Conway Acting Head of Global Human Resources
Kevin C. Mannix Senior Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Feb 12, 2024 10-K Annual Report
Feb 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Nov 8, 2023 8-K Current Report
Oct 4, 2023 8-K Current Report
Sep 28, 2023 8-K Current Report
Aug 24, 2023 8-K Current Report
Aug 2, 2023 8-K Current Report
Aug 2, 2023 10-Q Quarterly Report